Raymond Sanchez, MD

Sphinx Board of Directors

Raymond (Ray) Sanchez, MD is currently the Chief Medical Officer of Cerevel Therapeutics focused on the global development of novel and innovative treatments in CNS/Neuro-Psychiatry. He is a psychiatrist with over twenty years of academic, medical and pharmaceutical industry experience (CNS, Sleep/Circadian Rhythms, Analgesia and Digital Health). Ray has a proven history of global asset development resulting in regulatory approvals in multiple indications and formulations in compounds such as Abilify, Abilify Maintena and Rexulti, including the first FDA approved small molecule/digital combination therapy to monitor ingestion, Abilify MyCite. Ray has provided transformative executive medical leadership overseeing global development portfolios from early phase to late-stage programs with specific innovative study designs having significant business impact. He has been involved in the execution of effective interactions and negotiations with FDA (US), EMA (EU), Health Canada, PMDA (Japan) and TGA (Australia) on several regulatory submissions. Additionally, he provided strategic oversight of the Rexulti dual-indication launch in the US as well as medical affairs leadership with life-cycle management development and execution in the US, EU and Japan. He has a strong global network of academic and regulatory experts as well as clinical investigators with a history of effective collaboration and outcomes. He has extensive business development experience with due diligence of potential assets and alliance acquisitions and management as well as leveraging new technological approaches to pharmaceutical development. In 2019, Ray partnered with Bain Capital Life Sciences in building Cerevel Therapeutics with other seasoned executives, that included building the medical organizations, including capital formation and infrastructure build that led to a strong investor syndicate and an IPO in 2020. Ray was inducted as a member of the Neuroscience Forum of the Academies of Science, Engineering and Medicine. Additionally, Ray was the Northeast Representative of the American Psychiatric Association (APA) as well as an active member of the APA’s Legislative Institute in Washington, D.C. advocating for mental health parity on Capitol Hill. He was also one of six selected nationally to participate in the program in addiction psychiatry at the Betty Ford Center at Eisenhower Medical Center in Rancho Mirage, CA. He is the recipient of the prestigious “Top 100 Leaders in Healthcare” award by the International Forum on Advancements in Healthcare (IFAH) as well as one of the Pharma Leaders by Pharmaceutical Executive magazine. In 2023, Ray was named to the PharmaVoice 100, acknowledging his significant contributions to the Life Sciences as a clinical innovator. He has also served as Executive Chairman of the International Society for CNS Drug Development (ISCDD). He is on Board of Directors, Connecticut Mental Health Center Foundation-Yale School of Medicine, Board Director of the Life Re-Entry Foundation as well as other non-for-profit organizations. He is well-published and has participated in numerous scientific presentations. Ray received an A.B. in Psychology from the Weinberg College of Arts and Sciences at Northwestern University with Distinction and Phi Beta Kappa Honors, a M.D. from the Feinberg Medical School at Northwestern and trained in psychiatry at the Yale School of Medicine where he also was appointed as Chief Resident and an Instructor before joining the Life Sciences Industry.